Jivi®, Newly Approved by FDA > Publications

Jivi, on August 29, 2018, the FDA approved Jivi® (in clinical studies known as Antihemophilic Factor (Recombinant), PEGylated-aucl)

Jivi®, Newly Approved by FDA

By Leigh Carpenter, RPh, Director of Pharmacy

Published October 1, 2018

On August 29, 2018, the FDA approved Jivi® (in clinical studies known as Antihemophilic Factor (Recombinant), PEGylated-aucl). Jivi® is indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Jivi® is available in four vial sizes of assay ranges: 500, 1000, 2000, and 3000 iu. If you are interested in Jivi®, ask your hematologist about it at your next hemophilia treatment center visit.